Fig. 2From: Dolutegravir use over 48 weeks is not associated with worsening insulin resistance and pancreatic beta cell function in a cohort of HIV-infected Ugandan adultsChanges in mean insulin resistance (HOMA IR) over 48 weeksBack to article page